Introduction {#sec1_1}
============

Postprandial hyperinsulinemic hypoglycemia after bariatric surgery has been described as a new entity which is characterized by severe neuroglycopenic symptoms such as coma and seizures that can be disabling for the patient \[[@B1]\]. It is difficult to know the exact incidence as most studies describe patients with hypoglycemic events not depending on their severity and without a clear differentiation from the early and late dumping syndrome. However, according to the Swedish Nationwide cohort study, 0.2% of patients undergoing Roux-en-Y gastric bypass (RYGB) suffer from this complication \[[@B2]\].

Postprandial hyperinsulinemic hypoglycemia was initially attributed to hyperplasia of pancreatic islets consistent with nesiodioblastosis \[[@B3],[@B4]\]. Exaggerated GLP-1 response to meals after gastric bypass was proposed as the key factor promoting β-cell proliferation \[[@B1]\]. However, other authors observed an enlarged nuclear diameter of the β cell suggesting increased secretory activity \[[@B5]\]. Therefore, a functional rather than a structural pancreatic alteration has been hypothesized. However, the exact etiology has still to be elucidated \[[@B6],[@B7],[@B8],[@B9]\]. The published data regarding this entity include small series of patients, and not all of them were affected by severe hypoglycemia \[[@B10]\]. Moreover, among authors there is high heterogeneity in the definition of severe hypoglycemia, the diagnostic approach, and its treatment because to date there is no established consensus. In this sense, we collected data from patients with recurrent severe hypoglycemic episodes after bariatric surgery, events which brought them to the emergency room, not responding either to diet or adequately to α-glucosidase inhibitors. Our aim was to describe the different biochemical tests performed for the diagnosis of this entity and their outcomes, as well as the response to the prescribed pharmacological and surgical treatments.

Material and Methods {#sec1_2}
====================

This is a multicenter, retrospective a systematic review of cases with severe postprandial hypoglycemia after bariatric surgery. Subjects were selected from registered cohorts from Spanish referral hospitals followed by the Obesity Group of the Spanish Society of Endocrinology and Nutrition (GOSEEN) \[[@B11],[@B12]\].

Detailed clinical and biochemical data were retrospectively collected by reviewing medical charts of all patients who had previously undergone bariatric surgery (RYGB and malabsorptive procedures) during the period from January 2002 to December 2013 in the 12 tertiary reference public hospitals in Spain.

A severe episode of hypoglycemia was defined as a hypoglycemic event (venous glucose \< 50 mg/dl) \[[@B13]\] requiring attendance by the emergency services or hospitalization that occurred after bariatric surgery and was accompanied by neuroglycopenic symptoms in the absence of a pharmacological treatment which might explain their appearance. Patients were only included if they had undergone recurrent episodes of severe hypoglycemia that had not responded to diet modifications and showed an incomplete response to α-glucosidase inhibitors. Precocious and late dumping syndrome was clinically discarded since they usually respond to low-carbohydrate diet and frequent small split meals.

Data collected in the questionnaire included demographic and anthropometric characteristics of patients and a description of the hypoglycemic events. The laboratory tests, the radiological studies, and the performance of an arterial calcium stimulation test were registered. Medical treatments and pancreatic or reconstructive surgery used to manage the hypoglycemic events and their outcomes were recorded.

*Meal test* : In all centers, the patients arrived at the laboratory in the morning after an overnight fast. An antecubital venous cannula was inserted, and blood was extracted. Baseline glucose, insulin and C-peptide values were obtained in the hospital laboratory and at times 0, 30, 60, 90, 120, 150, 180 and 240 min after the liquid meal ingestion. In some centers, sample collection was finished after 120 min and in others after 180 min. Different products were used as a liquid test meal containing approximately 16% protein, 30% lipids and 54% carbohydrates with 250 kcal.

*Oral glucose challenge testing* was performed in some centers with 75 and in others with 100 g of glucose administered orally to evoke postprandial hypoglycemia. After an overnight fast, blood was extracted for hospital laboratory determination of glucose, insulin, C-peptide baseline values and at times 0, 30, 60, 90, 120, 150, 180 and 240 min. In some centers, sample collection was finished after 120 min and in others after 180 min.

This study was approved by the Ethic Committees of each hospital and is in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients signed a written informed consent which specified that data collected from their medical charts could be potentially used in an anonymous way for investigation and publication.

Statistical Analysis {#sec2_1}
--------------------

Data were expressed as mean ± SD for parametric variables and as frequencies for categorical variables. For categorical variables differences between groups were assessed with the chi-square test for independent samples. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS/Windows version 18; SPSS Inc., Chicago, IL, USA). Statistical significance was set at p \< 0.05.

Results {#sec1_3}
=======

Clinical Characteristics {#sec2_2}
------------------------

The total number of cases of hypoglycemia after bariatric surgery reported amounted to 22, with a total of 4,645 bariatric surgery interventions (RYGB and malabsorptive procedures) performed in the retrospective period analyzed (January 2002 to December 2013). Therefore, the estimated prevalence found in our series was 0.47%. However, this is a conservative estimate as it cannot be discarded that cases from our cohort had been attended in other hospitals.

21 women and 1 man, aged 51 ± 10 years, were included. The clinical characteristics of patients are given in table [1](#T1){ref-type="table"}. 19 patients (86.3%) had undergone a standard RYGB and 3 a malabsorptive procedure. Elapsed time since bariatric surgery was 31.8 ± 26 months (range 7-120 months). At the time of hypoglycemic episodes, 77% of patients had regained weight (10.7 ± 16% from their minimal weight after surgery). The hypoglycemic events were mainly postprandial, but 27% of patients presented with mixed episodes pre- and postprandially. Data relevant to the episodes of hypoglycemia are shown in table [2](#T2){ref-type="table"}.

Regarding the characteristics of patients, none suffered from hypoglycemic episodes before surgery, and type 2 diabetes was present in 9% of them remitting after the procedure, without requiring any hypoglycemic drugs.

Dynamic Tests {#sec2_3}
-------------

Only 3 (13.6%) of patients had plasma insulin concentrations determined during a spontaneous episode of hypoglycemia; in the remaining subjects, insulin and glucose levels were analyzed along with venous glucose sampling during the provocative test. The laboratory findings confirmed hyperinsulinemia or an inappropriate normal insulinemia in all patients and a concomitant venous glucose level of less than 50 mg/dl (mean 39.1 ± 9.3 mg/dl).

The test most used to provoke a hypoglycemic episode was the oral glucose load, which was performed in 16 (72%) patients. In 11 (50%) patients, a mixed meal test was done as an exclusive test (n = 3) and in addition to an oral glucose load (n = 8). During the oral glucose load, 81% of patients experienced a hypoglycemic event. In 2 patients, this test was not assessable because of vomiting. During the mixed meal test, 54% of patients had a hypoglycemic event. Comparing the 8 patients evaluated both with an oral glucose load and with a liquid mixed meal test, a greater proportion showed a positive result (presence of hypoglycemia) after the oral glucose load test (66% vs. 33%, p = 0,049). The mixed meal was the best tolerated test, although the least standardized. Different times of sample collection and total duration (ranging from 120 to 240 min) were reported. Also, different liquid meals were used containing 33-50 g of carbohydrates (mean 39.5 ± 5.3 g). A 72-hour fast was performed in 10 (45%) patients, mainly in patients with mixed pre- and postprandial episodes, and in 70% of them hypoglycemia was observed, but with low plasma insulin concentrations.

An exploratory glucose sensor was placed in only 3 patients, and hypoglycemic events were detected in all of them during a 5-day period. The continuous glucose monitoring of one of these patients (patient number 4) with persistent episodes of hypoglycemia can be seen in figure [1](#F1){ref-type="fig"}.

Therapy Strategies: Pharmacological Treatment {#sec2_4}
---------------------------------------------

The first step in the pharmacological treatment was the use of α-glucosidase inhibitors, only 4 patients (18%) showed a partial response (table [3](#T3){ref-type="table"}). A reduction of 50% in the number of hypoglycemic events and in their severity was considered a partial response. The second step was the use of a calcium channel blocker in 10 (45.4%) patients (nifedipine and verapamil at doses of 20 mg and 80 mg, respectively), and of diazoxide (mean dose 168.7 ± 94 mg/day) in 6 (27.2%). The results obtained with both previous treatments were similar, achieving an initial reduction of symptoms in 50% of patients. Octreotide was used as a second pharmacological treatment step after α-glucosidase inhibitors in 2 patients and as a third step in 11 patients (8 without response and 3 with partial response after calcium channel blockers / diazoxide). Among patients receiving octreotide, 5 (38.4%) showed a partial response and in 3 (23%) the hypoglycemic episodes resolved. Figure [2](#F2){ref-type="fig"} shows the continuous glucose monitoring of patient number 4 under octreotide treatment. In the follow-up, 2 patients with partial response under calcium channel blockers and diazoxide experienced a worsening of their symptoms. Therefore, with pharmacological treatment, 3 patients were symptom-free (with octreotide) and 12 experienced an attenuation of their hypoglycemic episodes (with α-glucosidase inhibitors n = 4, with calcium channel blockers n = 3, with octreotide n = 5). Seven patients with persistent severe hypoglycemic episodes underwent further studies.

Radiological Studies {#sec2_5}
--------------------

Abdominal CT and ecoendoscopy were performed in the former 7 patients, and octreotide scintigraphy was performed in 3 patients, without pathological findings. Selective arterial calcium stimulation was undertaken, and it was positive in 3 patients.

Surgical Treatment {#sec2_6}
------------------

Partial pancreatectomy was performed in 3 patients with positive selective arterial calcium stimulation. In 2 of them, neosidioblastosis was confirmed. After the intervention they were symptom-free, 1 or 2 years after surgery. In 1 patient, no histologically abnormal findings were observed, and hypoglycemic episodes persisted, requiring a reconversion of duodenal switch to original anatomy. However, 2 years later hypoglycemic episodes recurred and were controlled with α-glucosidase inhibitors during the next 3 years. After this period of time, type 2 diabetes mellitus was diagnosed and required treatment with insulin and metformin.

Redo surgery (revisional or conversional surgery) was chosen as a first surgical therapeutical option in 4 patients with previous RYGB. One of them underwent a 'kissing operation' with performance of an anastomosis between the alimentary limb and the antral remnant. However, 2 years later, because of recurrence, the alimentary limb was removed and the gastric pouch was anastomosed to the gastric remnant to restore the gastroduodenal tract continuity. The patient persisted with hypoglycemic episodes that could be controlled with α-glucosidase inhibitors. Two other patients underwent a complete reversal of RYGB to normal anatomy. The procedure consisted in dismantling the previous gastrojejunostomy and jejunojejunostomy, re-anastomosing the gastric pouch to the gastric remnant and the proximal alimentary limb end to the distal biliary limb end. The 2 patients have been without evidence of hypoglycemia for 1 year or for 3 months after the intervention. The last patient with RYGB (patient number 4) showed recurrence of hypoglycemic episodes after an initial resolution with octreotide. She underwent a gastric pouch restriction, reducing the anastomosis diameter and a resection of the nonfunctional Roux limb proximal to the jejunostomy in order to avoid the 'candy cane' Roux syndrome associated with hypoglycemia. The patient is symptom-free 1 year after the procedure (fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_4}
==========

Our series of 22 well-characterized patients with recurrent severe episodes of postprandial hypoglycemia, not responding to diet, is the largest published to date. In spite of the limitations, the estimated prevalence of 0.47% is a little higher than previously reported \[[@B2],[@B14]\] although the fact that we are referral hospitals could explain this difference. Nevertheless, our findings conformed the infrequence of this entity.

Previous reports described smaller cohorts of up to 9 cases, and they included patients suffering from late dumping \[[@B15],[@B16]\]. Our study only included patients with severe symptomatic hyperinsulinemic hypoglycemia with consistent biochemical and clinical data. Hyperinsulinemic severe hypoglycemia should be differentiated from early and late dumping syndrome that respond well to dietary manipulation and appear early in the postoperative period. More severe hypoglycemia, associated with neuroglycopenia, typically occurs 1-3 years after gastric bypass \[[@B3]\]. Indeed, in our patients hypoglycemic symptoms presented 32 months after surgery.

A greater prevalence of postoperative dumping syndrome among type 2 diabetic patients has been described in one previous paper \[[@B17]\]. However, this finding has not been confirmed in our series in which only 9% of patients had a prior history of type 2 diabetes.

In our study, different methods of diagnosing hyperinsulinemic hypoglycemic events were used. The easiest test is to determine venous glucose and insulin concentrations during a spontaneous episode of low plasma glucose. However, patients are usually attended at home or at the hospital emergency room, and insulin concentrations during the hypoglycemic episode cannot be easily determined. The tests used to induce hypoglycemia show low specificity, and, taking all the data together, it is not possible to recommend only one of them. The oral glucose tolerance test (OGTT) has historically been used for reactive hypoglycemia; however, it may not be well tolerated after gastric bypass and has been found to be positive (episode of hypoglycemia) in 10% of normal people \[[@B18]\] and 33% of patients with gastric bypass without hypoglycemia \[[@B19],[@B20]\]. The liquid meal test seems to be a more physiological stimulus with lower glucose load, but it can be positive in 30% of asymptomatic patients undergoing gastric bypass \[[@B21]\]. In our study, a greater proportion of patients experienced a hypoglycemic event during the OGTT than during the mixed meal. However, with the former test not all patients received 50 g of carbohydrates which could be the major physiological stimulus.

A glucose sensor can register low glucose episodes in free-living conditions. A recent study has described better detection rates of hypoglycemia with continuous glucose monitoring compared to mixed meal test \[[@B21]\]. However, its use is limited because it is not available to all centers, and the results obtained have to be supplemented by laboratory parameters \[[@B22]\].

The etiology of this entity is still unclear. Some authors have attributed it to the presence of nesidioblastosis but others have alternatively supported increased activity of β cells, probably induced by GLP-1 \[[@B1],[@B23]\]. However, the use of GLP-1 receptor antagonist, has not shown a different effect on insulin secretion in patients with and without recurrent hypoglycemia \[[@B24]\]. The case of a patient has been published in whom hypoglycemia was completely ameliorated by feeding via gastrostomy tube through the bypassed gut \[[@B25]\]. This suggested that in some cases there is a functional pancreatic alteration that may be resolved when food does not rapidly bypass the duodenum and arrives to the ileum. In this sense, this entity has only been described in gastric bypass and malabsorptive surgeries that exclude the proximal gut.

There is no 'gold-standard' medical treatment for severe hyperinsulinemic hypoglycemia \[[@B26],[@B27],[@B28],[@B29]\]. The pharmacological treatment is directed to reduce carbohydrate absorption, reduce insulin secretion, and slow gastric emptying. When the symptoms are refractory to diet the first pharmacological treatment used in our series is α-glucosidase inhibitors that are able to improve but not resolve symptoms in 18% of cases. In our experience, the second step is a calcium channel blocker because of its low cost and easy administration. One of the main mechanisms of action of calcium antagonists is a direct inhibitory effect on the pancreatic β-cell glucose-induced insulin release \[[@B30]\]. Some clinicians prefer a β-cell inhibitor diazoxide \[[@B10],[@B31],[@B32],[@B33]\] even though in our country it can only be prescribed in the hospital pharmacy as a foreign drug, with similar results compared to calcium antagonists in our experience (partial effect in 50% of patients and ineffective in the rest). The third step and increasingly being used as a second step is the secretory inhibitor octreotide. In our series, with this treatment 23% of patients had complete resolution of the hypoglycemic episodes. Therefore, octreotide could be the treatment of choice when diet, α-glucosidase and calcium channel blockers fail to control hypoglycemic episodes. Although it is expensive, needs subcutaneous administration and can only be prescribed in our country as compassionate use for the treatment of hyperinsulinemic hypoglycemia, different reports have shown how it specifically inhibits GLP-1 secretion \[[@B34]\].

Surgical therapy has to be considered when pharmacological treatment is unsuccessful. In our experience, reconversion to normal anatomy in one step is a safe process and the most successful technique. However, our follow-up is relatively short, and other authors have recently described persistence of hypoglycemia after reconversion \[[@B35]\]. Other surgical approaches have been used, such as restoring gastric restriction with an adjustable gastric band \[[@B36]\] or providing nutrition through a gastrostomy tube \[[@B25]\]. However, to date there is insufficient experience to recommend any of the previous approaches.

Partial or subtotal pancreatic resection is reserved when a gradient is found in venous sampling. In our series, 3 patients underwent pancreatic resection, and in 2 nesidioblastosis was confirmed with resolution of symptoms \[[@B37]\]. In another patient the histology showed no abnormalities and required restoring of gastrointestinal continuity with a final development of type 2 diabetes a few years later. Partial pancreatectomy carries morbimortality \[[@B38]\] and in our opinion should be reserved for cases with high suspicion of nesidioblastosis with a detailed radiologic study and a positive venous sampling. For the remaining cases, reconversion to original anatomy might be a safer procedure.

The present study has several limitations, the most important being that it is retrospective. However, a systemized revision of cases was performed, and only patients with clinical severe recurrent hypoglycemia with confirmed biochemical parameters were included. Different diagnostic tests and medical treatments were used as there are no established guidelines regarding the management of this complication, highlighting the need for their elaboration.

Conclusions {#sec1_5}
===========

Postoperative hypoglycemia is an uncommon, yet troublesome, side effect after RYGB. There is high heterogeneity in the initial evaluation and treatment options, and most authors follow their own experience as there is no established consensus. Approximately 30% of these episodes will not respond to pharmacological treatment involving α-glucosidase, calcium channel antagonists, diazoxide, and octreotide. In these cases radiological studies and a calcium stimulation test should be performed. Reconstruction of gastrojejunal continuity might be the safest and most successful option. Partial or subtotal pancreatic resection has high morbimortality, can lead to the onset of diabetes and should be applied only when a clear gradient is found in venous sampling.
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![Continuous glucose monitoring pre-pharmacological treatment. Each line represents an individual day. Y-axes represent glucose (mg/dl), X-axes represent hour of the day. Glucose values below 50 mg/dl are indicated in red and they represent 8% of all glycemic values.](ofa-0009-0041-g01){#F1}

![Continuous glucose monitoring under octreotide treatment. Each line represents an individual day. Y-axes represent glucose (mg/dl), X-axes represent hour of the day. Glucose values below 50 mg/dl are indicated in red. Only one value of glucose below 50 mg/dl was detected. On the contrary, due to side effects of the medication, hyperglycemia (glucose \> 150 mg/dl) was detected on a few ocasions.](ofa-0009-0041-g02){#F2}

![Continuous glucose monitoring after revisional surgery. Each line represents an individual day. Y-axes represent glucose (mg/dl), X-axes represent hour of the day. Six months after the resection of the 'candy cane' roux limb no hypoglycemia was observed.](ofa-0009-0041-g03){#F3}

###### 

Clinical characteristics of patients and laboratory values during episodes of postprandial hypoglycemia

                                                                                           N
  ---------------------------------------------------------------------------------------- -------------
  Sex (M/F)                                                                                1/21
                                                                                           
  Age, years                                                                               51 ±10
                                                                                           
  Type of surgery, n (%)                                                                   
   Roux-en-Y gastric bypass                                                                19 (86.3%)
   Biliopancreatic diversion                                                               2 (9.2 %)
   Duodenal switch                                                                         1 (4.5%)
                                                                                           
  Time after surgery, months                                                               31.8 ± 26
                                                                                           
  Frequency of hypoglycemias, n (%)                                                        
   Daily episodes                                                                          13 (59.0%)
   2--3 episodes/week                                                                      2 (9.2%)
   Weekly episodes                                                                         7 (31.8%)
                                                                                           
  Serum glucose during episode of hypoglycemia, mg/dl                                      39.2 ± 9.3
                                                                                           
  Serum insulin during episode of hypoglycemia (normal range 2.3 -- 16.7 μUI/ml), μUI/ml   15.9 ± 13.7
                                                                                           
  Effects of hypoglycemia                                                                  
   Falls and contusions                                                                    54.7%
   Coma                                                                                    13.6%
   Continuous invalidating faints                                                          22.7%
   Seizures                                                                                9.0%

###### 

Clinical characteristics of the episodes of spontaneous postprandial hypoglycemia

                                                   N (%)
  ------------------------------------------------ ------------
  Type of hypoglycemias                            
   Postprandial                                    16 (72.7%)
   Mixed                                           6 (27.3%)
                                                   
  Frequency of hypoglycemias                       
   Daily episodes                                  13 (59.0%)
   2 -- 3 episodes/week                            2 (9.2%)
   Weekly episodes                                 7 (31.8%)
                                                   
  Acute treatment of the episode                   
   Simple carbohydrates (oral)                     7 (31.8%)
   Glucose (iv)                                    4 (18.2%)
   Glucagon (subcut)                               1 (4.5%)
   Simple carbohydrates +glucose (iv)              4 (18.2%)
   Simple carbohydrates + glucagon (subcut)        2 (9.1%)
   All previous treatments on different episodes   2 (9.1%)
                                                   
  Effects of hypoglycemia                          
   Falls and contusions                            54.7%
   Coma                                            13.6%
   Continuous invalidating faints                  22.7%
   Seizures                                        9.0%

###### 

Response to pharmacological treatment

  Medication                     Dose                              Number of patients                   No response   Partial response   Complete response
  ------------------------------ --------------------------------- ------------------------------------ ------------- ------------------ -------------------
  Alpha glucosidase inhibitors   50 mg / 8 h orally                22                                   18 (82%)      4 (18%)            0
                                                                                                                                         
  Nifedipine plus verapamil      20 mg/day 80 mg/day orally        10                                   5 (50%)       5 (50%)            0
                                                                                                                                         
  Diazoxide                      168.7 ± 94 mg/day orally          6                                    3 (50%)       3 (50%)            0
                                                                                                                                         
  Octreotide                     50/100 μg / 12 h subcutaneously   13[\*](#T3F1){ref-type="table-fn"}   5 (38,4%)     5 (38,4%)          3 (23%)

N= 2 patients after alpha glucosidase inhibitors + N = 11 after calcium channel blocker / diazoxide.
